caffeine and Disease Models, Animal studies

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
" Similarly, the consumption of caffeine antagonizes A2ARs, resulting in exacerbation of ongoing acute inflammation."	8.85	The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. ( Belikoff, B; Hatfield, S; Lukashev, D; Ohta, A; Sitkovsky, M, 2009)
"Combination of curcumin with anti-inflammatory drug like caffeine shows augmented antipsoriatic action compared to curcumin alone and reduce the time taken for treatment of Psoriasis."	7.96	Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis. ( Balamuralidhara, V; Gupta, NV; Iriventi, P; Osmani, RAM, 2020)
"Caffeine treatment can protect hyperoxia-induced mice lung from oxidative injury by inhibiting NLRP3 inflammasome and NF-κB pathway."	7.96	Caffeine prevents hyperoxia-induced lung injury in neonatal mice through NLRP3 inflammasome and NF-κB pathway. ( Chen, S; Du, L; Li, C; Wu, Q; Zhong, D, 2020)
"Osteosarcoma PDOX models were randomly divided into seven treatment groups (6 mice in each group): untreated control; CDDP alone; o-rMETase alone; o-rMETase with caffeine; CDDP plus o-rMETase; CDDP plus caffeine; and CDDP plus o-rMETase with caffeine."	7.91	Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. ( Bouvet, M; Chawla, SP; Han, Q; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Park, J; Razmjooei, S; Singh, SR; Sugisawa, N; Tan, Y; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019)
"Anxiety is a common symptom associated with high caffeine intake."	7.91	Oxidative Stress Mediates Anxiety-Like Behavior Induced by High Caffeine Intake in Zebrafish: Protective Effect of Alpha-Tocopherol. ( Assad, N; Bahia, CP; Brasil, A; Cardoso, PB; de Carvalho, TS; de Jesus Oliveira Batista, E; Gouveia, A; Herculano, AM; Kauffmann, N; Lima-Bastos, S; Luz, WL; Moraes, S; Oliveira, KRMH; Passos, A; Santos-Silva, M, 2019)
"Caffeine intake is associated with a reduced risk developing non-alcoholic fatty liver disease (NAFLD), but the underlying molecular mechanisms remain to be fully elucidated."	7.91	Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. ( Akira, S; Cai, X; Fang, C; Fujiwara, N; Hao, S; Hayashi, S; Nishiguchi, S; Sakiyama, H; Sheng, J; Tsutsui, H; Wang, X; Yang, Q, 2019)
"In addition to the pharmacological antagonism of adenosine receptors, caffeine appears to be a potent antioxidant and modulates the hyperoxia-induced pulmonary oxidative stress response and thus protective properties in the BPD-associated animal model."	7.91	Antioxidative effects of caffeine in a hyperoxia-based rat model of bronchopulmonary dysplasia. ( Bührer, C; Endesfelder, S; Scheuer, T; Schmitz, T; Strauß, E, 2019)
"Caffeine and hyperoxia in itself upregulate HIF-2α and vascular endothelial growth factor gene expression."	7.91	Caffeine is associated with improved alveolarization and angiogenesis in male mice following hyperoxia induced lung injury. ( Dumpa, V; Kumar, VHS; Nielsen, L; Wang, H, 2019)
"This study was designed to assess the role of caffeine on fertility parameters in testicular and epididymal tissues of scopolamine-induced model of amnesia in rats."	7.91	Caffeine improves sperm quality, modulates steroidogenic enzyme activities, restore testosterone levels and prevent oxidative damage in testicular and epididymal tissues of scopolamine-induced rat model of amnesia. ( Akomolafe, SF; Oboh, G; Ogunsuyi, OB; Olasehinde, TA; Oyeleye, SI, 2019)
"Caffeine is widely used to manage apnea of prematurity, and reduces the incidence of bronchopulmonary dysplasia (BPD)."	7.85	Caffeine administration modulates TGF-β signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia. ( Agius, R; Herold, S; Hühn, S; Mayer, K; Mižíková, I; Morty, RE; Nardiello, C; Rath, P; Runkel, F; Seeger, W; Surate Solaligue, DE; Vadász, I, 2017)
"Preterm New Zealand-Dendermonde rabbits (gestational day 28; term 31) were randomized to three groups: normoxia-placebo (N-P), hyperoxia-placebo (H-P) and hyperoxia-caffeine (H-C)."	7.83	Caffeine Prevents Hyperoxia-Induced Functional and Structural Lung Damage in Preterm Rabbits. ( Allegaert, K; Croubels, S; De Baere, S; Deprest, JA; Jiménez, J; Nagatomo, T; Naulaers, G; Richter, J; Toelen, J; Vanoirbeek, J, 2016)
"Apnea of prematurity, which is prevalent among infants born at less than 34 weeks gestation, is treated with caffeine, theophylline, or aminophylline."	7.81	Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. ( Ding, X; Greer, JJ; Ren, J, 2015)
"Development of acute colitis is reduced upon caffeine treatment."	7.80	Oral caffeine administration ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial cells. ( Kamba, A; Lee, IA; Llado, V; Low, D; Mizoguchi, E, 2014)
"We hypothesized that caffeine improves respiratory function via an anti-inflammatory effect in lungs of a lipopolysaccharide (LPS)-induced pro-inflammatory amnionitis rat pup model."	7.80	Anti-inflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitis. ( Balan, KV; Jafri, A; Kc, P; Köroğlu, OA; MacFarlane, PM; Martin, RJ; Zenebe, WJ, 2014)
" Since caffeine (an adenosine receptor antagonist) and selective antagonists of adenosine A2A receptors modify the course of memory impairment in different amyloid-β-based experimental models of AD, we now tested the impact of caffeine on STZ-induced dementia and associated neurodegeneration in the hippocampus as well as on the expression and density of adenosine receptors."	7.79	Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. ( Costa, MS; Cunha, RA; Espinosa, J; Kalinine, E; Kazlauckas, V; Nunes, F; Porciúncula, LO; Rocha, A; Schein, V; Souza, DO, 2013)
" The presence of several bioactive compounds, such as polyphenols and caffeine, implicates coffee as a potential nutritional therapeutic in aging."	7.79	Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging. ( Chu, YF; Joseph, JA; Lyle, BJ; Miller, MG; Shukitt-Hale, B, 2013)
"The Methyl Xanthine caffeine inhibits the DNA damage response in vitro and in vivo, regulates both cell proliferation and apoptosis after DNA damage, inhibits reactive species, and reduces atherogenesis in ApoE(-/-) mice."	7.78	The methyl xanthine caffeine inhibits DNA damage signaling and reactive species and reduces atherosclerosis in ApoE(-/-) mice. ( Bennett, MR; Figg, N; Gray, K; Kumar, S; Mercer, JR, 2012)
"Our data suggest that adenosine through its A(2A)R promotes peritoneal fibrosis and therefore should be considered as a target for pharmacological intervention."	7.75	Blocking adenosine A2A receptor reduces peritoneal fibrosis in two independent experimental models. ( Chaimovitz, C; Douvdevani, A; Kachko, L; Nakav, S; Rogachev, B; Vorobiov, M; Zlotnik, M, 2009)
"This study compared effects of the mu opioid receptor agonist morphine (an acknowledged analgesic), the dopamine receptor antagonist haloperidol (a non-analgesic sedative), the adenosine receptor antagonist caffeine (a non-analgesic stimulant) and the neurokinin-1 receptor antagonist CJ 11,974-01 (a candidate analgesic) on acetic acid-induced writhing (a traditional pain-stimulated behavior) and acetic acid-induced suppression of locomotor activity (a pain-depressed behavior) in male ICR mice."	7.75	Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. ( Adams, C; Bilsky, EJ; Cormier, J; Dunbar, C; Mercer, H; Negus, SS; Stevenson, GW, 2009)
" The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice."	7.73	Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005)
"To investigate the consequences of caffeine consumption on epileptic seizures, we used the pilocarpine and the kainate models of epilepsy."	7.73	Consequences of prolonged caffeine administration and its withdrawal on pilocarpine- and kainate-induced seizures in rats. ( Hoexter, MQ; Mello, LE; Rosa, PS; Tufik, S, 2005)
"Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression."	7.72	Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003)
" Recent studies have shown beneficial effects of an adenosine A(2A) receptor agonist in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress and consumption of coffee can precipitate dystonic attacks."	7.71	Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. ( Hamann, M; Richter, A, 2001)
"This study was designed to determine (1) whether chronic amitriptyline administration was effective in alleviating symptoms of neuropathic pain in a rat model of spinal nerve injury, and (2) whether the effect of amitriptyline involved manipulation of endogenous adenosine, by determining the effect of caffeine, a non-selective adenosine A(1) and A(2) receptor antagonist, on its actions."	7.71	Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. ( Allen, GV; Chase, T; Esser, MJ; Sawynok, J, 2001)
"Recent studies suggest an association between caffeine consumption and tremor."	7.71	Effect of acute caffeine on severity of harmaline induced tremor in rats. ( Al-Deeb, S; Al-Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2002)
"In the present study, we sought to determine whether administration of caffeine, a non-selective adenosine receptor antagonist, would affect the thermal antihyperalgesic efficacy of acute amitriptyline in a rat model of neuropathic pain."	7.70	Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. ( Esser, MJ; Sawynok, J, 2000)
"Despite significant progress in understanding of the potential of adenosine A1 receptor-based therapies in treatment of cerebral ischemia and stroke, very little is known about the effect of selective stimulation of adenosine A2A receptors on the outcome of a cerebrovascular arrest."	7.69	Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. ( Jacobson, KA; Lin, RC; Von Lubitz, DK, 1995)
"The inherited disease Lesch-Nyhan syndrome, which is caused by a deficiency of the enzyme hypoxanthine phosphoribosyltransferase (HPRT), is characterized by behavioural alterations, including self-injurious behaviour and mental retardation."	7.68	Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. ( Melton, DW; Wu, CL, 1993)
"Rats ingesting high doses of caffeine reproduce the self-destructive behaviour observed in the Lesch-Nyhan syndrome."	7.67	Lesch-Nyhan syndrome, caffeine model: increase of purine and pyrimidine enzymes in rat brain. ( Grisolía, S; Jordá, A; Miñana, MD; Portolés, M, 1984)
"Caffeine is a most widely consumed physiological stimulant worldwide, which is consumed via natural sources, such as coffee and tea, and now marketed sources such as energy drinks and other dietary supplements."	6.53	Caffeine and cardiovascular diseases: critical review of current research. ( Hayes, A; Klimas, J; Kobyliak, N; Kruzliak, P; Kubatka, P; La Rocca, G; Loftus, H; Novak, J; Pohanka, M; Qaradakhi, T; Smith, RM; Soucek, M; Uehara, Y; Zagatina, A; Zulli, A, 2016)
" However, long-term administration of this approach is linked to several complications, and a definitive gold-standard therapy for PD is yet to be identified."	5.91	Caffeine alleviates anxiety-like behavior and brainstem lesions in a rotenone-induced rat model of Parkinson's disease. ( Adeyeye, TA; Babatunde, BR; Ehireme, SE; Shallie, PD, 2023)
"Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy."	5.72	Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022)
"Caffeine-treated and -untreated pups underwent the Vannucci procedure (unilateral carotid ligation, global hypoxia) on P2."	5.56	Caffeine Restores Background EEG Activity Independent of Infarct Reduction after Neonatal Hypoxic Ischemic Brain Injury. ( Gonzalez, F; McQuillen, PS; Sun, H, 2020)
"Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity."	5.43	Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016)
"Caffeine is able to increase the effect of rac-Flur in the arthritic gout-type pain in rats."	5.43	Antinociceptive Effect of Racemic Flurbiprofen and Caffeine Co-Administration in an Arthritic Gout-Type Pain in Rats. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; Liévano-Reyes, R; López-Muñoz, FJ; Pérez-Méndez, HI; Solís-Oba, A, 2016)
"Caffeine, which is an antagonist of adenosine receptors, is the most widely consumed psychoactive drug in the world."	5.43	Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma. ( Agudo-Barriuso, M; Ambrósio, AF; Madeira, MH; Nadal-Nícolas, F; Ortin-Martinez, A; Santiago, AR; Vidal-Sanz, M, 2016)
"d-galactose has been considered a senescent model for age-related neurodegenerative disease."	5.42	Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. ( Ali, T; Kim, MO; Ullah, F; Ullah, N, 2015)
"Caffeine treatment resulted in the recovery of fructose-induced decrease in nitric oxide production in the NTS."	5.40	Caffeine intake improves fructose-induced hypertension and insulin resistance by enhancing central insulin signaling. ( Chen, BR; Cheng, PW; Cheng, WH; Ho, WY; Liou, JC; Liu, CP; Lu, PJ; Sun, GC; Tseng, CJ; Yeh, TC, 2014)
"Caffeine (1g/L) was applied through the drinking water."	5.39	Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. ( Cunha, RA; de Almeida, LP; Gonçalves, N; Simões, AT, 2013)
"Caffeine is a nonselective adenosine receptor antagonist; chronic consumption has proved protective toward neurodegenerative diseases such as Parkinson's and Alzheimer's diseases."	5.39	Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. ( Armida, M; Ferrante, A; Matteucci, A; Pèzzola, A; Popoli, P; Potenza, RL; Puopolo, M, 2013)
"Melatonin was tested in two experimental groups, one of which underwent common bile duct ligation for 2 days and another that was later de-ligated for 2 days."	5.35	Protective effect of melatonin on Ca2+ homeostasis and contractility in acute cholecystitis. ( Camello, PJ; Gomez-Pinilla, PJ; Pozo, MJ, 2008)
"Occurrence of seizures following long-term oral administration of caffeine (0."	5.35	Evidence for the involvement of the adenosine A(2A) receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine. ( Costentin, J; El Yacoubi, M; Ledent, C; Parmentier, M; Vaugeois, JM, 2008)
"Caffeine treatment augmented A1AR expression on microglia, with ensuing reduction of EAE severity, which was further enhanced by concomitant treatment with the A1AR agonist, adenosine amine congener."	5.32	A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. ( Henry, S; Noorbakhsh, F; Power, C; Schnermann, J; Tsutsui, S; Warren, K; Winston, BW; Yong, VW, 2004)
" Similarly, the consumption of caffeine antagonizes A2ARs, resulting in exacerbation of ongoing acute inflammation."	4.85	The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. ( Belikoff, B; Hatfield, S; Lukashev, D; Ohta, A; Sitkovsky, M, 2009)
"Experimental data indicate that caffeine (CAF) can reduce the anticonvulsant activity of antiepileptic drugs (AEDs) in animal models of seizures."	4.12	Effect of caffeine on the anticonvulsant action of pregabalin against electroconvulsions in mice. ( Chwedorowicz, R; Czuczwar, SJ; Raszewski, G; Łukawski, K, 2022)
" We validated this as anxiety-like behaviors with diazepam reducing, and caffeine increasing the time spent in the bottom of the novel environment."	4.12	The larval diving response (LDR): Validation of an automated, high-throughput, ecologically relevant measure of anxiety-related behavior in larval zebrafish (Danio rerio). ( Fontana, BD; Parker, MO, 2022)
"To investigate whether caffeine can be useful for control of inflammation derived from experimental systemic infection with Listeria monocytogenes."	4.02	Anti-inflammatory activity of caffeine (1,3,7-trimethylxanthine) after experimental challenge with virulent Listeria monocytogenes in Swiss mice. ( de Alcântara Almeida, I; Mancebo Dorvigny, B; Nunes Santana, L; Souza Tavares, L; Vitor Lima-Filho, J, 2021)
" A mouse model is presented that captures inflammation-associated cortical slow wave activity (SWA) observed in patients, allowing exploration of the mechanistic role of prostaglandin-adenosine signalling."	4.02	Electrophysiological signatures of acute systemic lipopolysaccharide-induced inflammation: potential implications for delirium science. ( Banks, MI; Grady, SM; Jaeckel, ER; Krause, BM; Murphy, CA; Sanders, RD; Sultan, ZW, 2021)
"Combination of curcumin with anti-inflammatory drug like caffeine shows augmented antipsoriatic action compared to curcumin alone and reduce the time taken for treatment of Psoriasis."	3.96	Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis. ( Balamuralidhara, V; Gupta, NV; Iriventi, P; Osmani, RAM, 2020)
"Caffeine treatment can protect hyperoxia-induced mice lung from oxidative injury by inhibiting NLRP3 inflammasome and NF-κB pathway."	3.96	Caffeine prevents hyperoxia-induced lung injury in neonatal mice through NLRP3 inflammasome and NF-κB pathway. ( Chen, S; Du, L; Li, C; Wu, Q; Zhong, D, 2020)
"Osteosarcoma PDOX models were randomly divided into seven treatment groups (6 mice in each group): untreated control; CDDP alone; o-rMETase alone; o-rMETase with caffeine; CDDP plus o-rMETase; CDDP plus caffeine; and CDDP plus o-rMETase with caffeine."	3.91	Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. ( Bouvet, M; Chawla, SP; Han, Q; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Park, J; Razmjooei, S; Singh, SR; Sugisawa, N; Tan, Y; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019)
"Anxiety is a common symptom associated with high caffeine intake."	3.91	Oxidative Stress Mediates Anxiety-Like Behavior Induced by High Caffeine Intake in Zebrafish: Protective Effect of Alpha-Tocopherol. ( Assad, N; Bahia, CP; Brasil, A; Cardoso, PB; de Carvalho, TS; de Jesus Oliveira Batista, E; Gouveia, A; Herculano, AM; Kauffmann, N; Lima-Bastos, S; Luz, WL; Moraes, S; Oliveira, KRMH; Passos, A; Santos-Silva, M, 2019)
"Caffeine intake is associated with a reduced risk developing non-alcoholic fatty liver disease (NAFLD), but the underlying molecular mechanisms remain to be fully elucidated."	3.91	Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. ( Akira, S; Cai, X; Fang, C; Fujiwara, N; Hao, S; Hayashi, S; Nishiguchi, S; Sakiyama, H; Sheng, J; Tsutsui, H; Wang, X; Yang, Q, 2019)
"In addition to the pharmacological antagonism of adenosine receptors, caffeine appears to be a potent antioxidant and modulates the hyperoxia-induced pulmonary oxidative stress response and thus protective properties in the BPD-associated animal model."	3.91	Antioxidative effects of caffeine in a hyperoxia-based rat model of bronchopulmonary dysplasia. ( Bührer, C; Endesfelder, S; Scheuer, T; Schmitz, T; Strauß, E, 2019)
"Caffeine and hyperoxia in itself upregulate HIF-2α and vascular endothelial growth factor gene expression."	3.91	Caffeine is associated with improved alveolarization and angiogenesis in male mice following hyperoxia induced lung injury. ( Dumpa, V; Kumar, VHS; Nielsen, L; Wang, H, 2019)
"This study was designed to assess the role of caffeine on fertility parameters in testicular and epididymal tissues of scopolamine-induced model of amnesia in rats."	3.91	Caffeine improves sperm quality, modulates steroidogenic enzyme activities, restore testosterone levels and prevent oxidative damage in testicular and epididymal tissues of scopolamine-induced rat model of amnesia. ( Akomolafe, SF; Oboh, G; Ogunsuyi, OB; Olasehinde, TA; Oyeleye, SI, 2019)
"Caffeine negatively mediates bone homeostasis to cause bone loss and even osteoporosis."	3.88	β-Estradiol antagonizes the inhibitory effects of caffeine in BMMSCs via the ERβ-mediated cAMP-dependent PKA pathway. ( Guan, X; Wang, C; Wang, H; Yu, M; Zhou, Y, 2018)
"We induced generalized tonic-clonic seizures with the administration of 60 mg/kg pentylenetetrazole (PTZ) in male Wistar Albino rats."	3.85	The Effects of Adenosinergic Modulation on Cytokine Levels in a Pentylenetetrazole-Induced Generalized Tonic-Clonic Seizure Model. ( Ateş, N; Dede, F; Eraldemir, FC; Karadenizli, S; Özsoy, ÖD; Şahin, D, 2017)
"Caffeine is widely used to manage apnea of prematurity, and reduces the incidence of bronchopulmonary dysplasia (BPD)."	3.85	Caffeine administration modulates TGF-β signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia. ( Agius, R; Herold, S; Hühn, S; Mayer, K; Mižíková, I; Morty, RE; Nardiello, C; Rath, P; Runkel, F; Seeger, W; Surate Solaligue, DE; Vadász, I, 2017)
"Preterm New Zealand-Dendermonde rabbits (gestational day 28; term 31) were randomized to three groups: normoxia-placebo (N-P), hyperoxia-placebo (H-P) and hyperoxia-caffeine (H-C)."	3.83	Caffeine Prevents Hyperoxia-Induced Functional and Structural Lung Damage in Preterm Rabbits. ( Allegaert, K; Croubels, S; De Baere, S; Deprest, JA; Jiménez, J; Nagatomo, T; Naulaers, G; Richter, J; Toelen, J; Vanoirbeek, J, 2016)
" After three weeks as a recovery period, 6-OHDA-induced bradykinesia and balance disturbances were assessed by using beam traversal test 10, 30 and 60 minutes after intraperitoneal injections of the drugs (caffeine, SCH58261)."	3.83	Effect of adenosine A2A receptor antagonists on motor disorders induced by 6-hydroxydopamine in rat. ( Mahmoudi, J; Reyhani-Rad, S, 2016)
"Together with findings from the human literature, our results suggest that caffeine co-consumption may positively influence binge alcohol consumption in adolescents/young adults."	3.83	Concomitant Caffeine Increases Binge Consumption of Ethanol in Adolescent and Adult Mice, But Produces Additive Motor Stimulation Only in Adolescent Animals. ( Boehm, SL; Fritz, BM; Kasten, CR; Quoilin, C; Smoker, M, 2016)
" Then, we combined it with different doses of psychostimulants (d-amphetamine, modafinil, caffeine) to find the best combination for motion sickness."	3.83	The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness. ( Han, B; Liu, AJ; Liu, HQ; Song, XR; Tian, JS; Yu, XH; Zhang, LL; Zhang, Y, 2016)
"Apnea of prematurity, which is prevalent among infants born at less than 34 weeks gestation, is treated with caffeine, theophylline, or aminophylline."	3.81	Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. ( Ding, X; Greer, JJ; Ren, J, 2015)
"The influence of caffeine on epileptic seizures remains a matter of debate."	3.81	Effect of caffeine and adenosine receptor ligands on the expression of spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg (GAERS). ( Faure, JB; Germé, K; Koning, E; Nehlig, A, 2015)
"Development of acute colitis is reduced upon caffeine treatment."	3.80	Oral caffeine administration ameliorates acute colitis by suppressing chitinase 3-like 1 expression in intestinal epithelial cells. ( Kamba, A; Lee, IA; Llado, V; Low, D; Mizoguchi, E, 2014)
"We hypothesized that caffeine improves respiratory function via an anti-inflammatory effect in lungs of a lipopolysaccharide (LPS)-induced pro-inflammatory amnionitis rat pup model."	3.80	Anti-inflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitis. ( Balan, KV; Jafri, A; Kc, P; Köroğlu, OA; MacFarlane, PM; Martin, RJ; Zenebe, WJ, 2014)
" ECG telemetry revealed that various types of arrhythmias were induced in RyR2(R420W/R420W) mice in response to administration of caffeine and adrenaline."	3.80	A knock-in mouse model of N-terminal R420W mutation of cardiac ryanodine receptor exhibits arrhythmogenesis with abnormal calcium dynamics in cardiomyocytes. ( Hirata, Y; Kuwahara, M; Nishio, H; Oku, Y; Okudaira, N, 2014)
"Our previous studies demonstrated that the topical application of caffeine is a potent inhibitor of UVB-induced carcinogenesis and selectively increases apoptosis in tumors but not in non-tumor areas of the epidermis in mice that are at a high risk for developing skin cancer."	3.80	PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis. ( Bernard, JJ; Li, T; Lou, YR; Lu, YP; Peng, QY, 2014)
"Previous studies have shown that caffeine prevents the formation of cataracts induced by a high-galactose diet and consequent oxidative stress."	3.79	Protective effect of caffeine against high sugar-induced transcription of microRNAs and consequent gene silencing: a study using lenses of galactosemic mice. ( Kovtun, S; Varma, SD, 2013)
" Since caffeine (an adenosine receptor antagonist) and selective antagonists of adenosine A2A receptors modify the course of memory impairment in different amyloid-β-based experimental models of AD, we now tested the impact of caffeine on STZ-induced dementia and associated neurodegeneration in the hippocampus as well as on the expression and density of adenosine receptors."	3.79	Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. ( Costa, MS; Cunha, RA; Espinosa, J; Kalinine, E; Kazlauckas, V; Nunes, F; Porciúncula, LO; Rocha, A; Schein, V; Souza, DO, 2013)
" The presence of several bioactive compounds, such as polyphenols and caffeine, implicates coffee as a potential nutritional therapeutic in aging."	3.79	Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging. ( Chu, YF; Joseph, JA; Lyle, BJ; Miller, MG; Shukitt-Hale, B, 2013)
" CUS-exposed rats showed depressive-like behavior with reduced weight gain, reduced consumption of sucrose solution, increased immobility in the forced swimming test, and hypolocomotion in an open field."	3.78	Effect of long-term caffeine administration on depressive-like behavior in rats exposed to chronic unpredictable stress. ( Alova, LH; Nikolov, RP; Pechlivanova, DM; Petkov, VV; Tchekalarova, JD; Yakimova, KS, 2012)
"The Methyl Xanthine caffeine inhibits the DNA damage response in vitro and in vivo, regulates both cell proliferation and apoptosis after DNA damage, inhibits reactive species, and reduces atherogenesis in ApoE(-/-) mice."	3.78	The methyl xanthine caffeine inhibits DNA damage signaling and reactive species and reduces atherosclerosis in ApoE(-/-) mice. ( Bennett, MR; Figg, N; Gray, K; Kumar, S; Mercer, JR, 2012)
"We evaluated the wake-promoting efficacy of paraxanthine, caffeine, and a reference wake-promoting compound, modafinil, in a mice model of narcolepsy, a prototypical disease model of hypersomnia."	3.76	Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. ( Fujiki, N; Ishimaru, Y; Kotorii, N; Nishino, S; Okuro, M; Sokoloff, P, 2010)
"Our data suggest that adenosine through its A(2A)R promotes peritoneal fibrosis and therefore should be considered as a target for pharmacological intervention."	3.75	Blocking adenosine A2A receptor reduces peritoneal fibrosis in two independent experimental models. ( Chaimovitz, C; Douvdevani, A; Kachko, L; Nakav, S; Rogachev, B; Vorobiov, M; Zlotnik, M, 2009)
"This study compared effects of the mu opioid receptor agonist morphine (an acknowledged analgesic), the dopamine receptor antagonist haloperidol (a non-analgesic sedative), the adenosine receptor antagonist caffeine (a non-analgesic stimulant) and the neurokinin-1 receptor antagonist CJ 11,974-01 (a candidate analgesic) on acetic acid-induced writhing (a traditional pain-stimulated behavior) and acetic acid-induced suppression of locomotor activity (a pain-depressed behavior) in male ICR mice."	3.75	Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. ( Adams, C; Bilsky, EJ; Cormier, J; Dunbar, C; Mercer, H; Negus, SS; Stevenson, GW, 2009)
"Amitriptyline is used to treat neuropathic pain in humans."	3.74	Caffeine reverses antinociception by amitriptyline in wild type mice but not in those lacking adenosine A1 receptors. ( Fredholm, BB; Reid, AR; Sawynok, J, 2008)
" The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice."	3.73	Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005)
"To investigate the consequences of caffeine consumption on epileptic seizures, we used the pilocarpine and the kainate models of epilepsy."	3.73	Consequences of prolonged caffeine administration and its withdrawal on pilocarpine- and kainate-induced seizures in rats. ( Hoexter, MQ; Mello, LE; Rosa, PS; Tufik, S, 2005)
"The work shows the effects of caffeine after the intrastriatal injection of 6-OHDA in rats, considered as a model of Parkinson disease (PD)."	3.73	Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. ( Aguiar, LM; Cunha, GM; Freitas, RM; Macêdo, DS; Nobre, HV; Oliveira, AA; Sousa, FC; Vasconcelos, SM; Viana, GS, 2006)
"3 g/L) for 15 days before the induction of status epilepticus (SE) by lithium-pilocarpine and for 7 days after SE."	3.72	Prolonged low-dose caffeine exposure protects against hippocampal damage but not against the occurrence of epilepsy in the lithium-pilocarpine model in the rat. ( Ferrandon, A; Koning, E; Leroy, C; Nehlig, A; Rigoulot, MA, 2003)
"The effects of toluene on the sensitivity to seizures induced by aminophylline were investigated."	3.72	Toluene exposure increases aminophylline-induced seizure susceptibility in mice. ( Chan, MH; Chen, HH, 2003)
"Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression."	3.72	Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003)
"Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA."	3.71	An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001)
" Recent studies have shown beneficial effects of an adenosine A(2A) receptor agonist in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress and consumption of coffee can precipitate dystonic attacks."	3.71	Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. ( Hamann, M; Richter, A, 2001)
"This study was designed to determine (1) whether chronic amitriptyline administration was effective in alleviating symptoms of neuropathic pain in a rat model of spinal nerve injury, and (2) whether the effect of amitriptyline involved manipulation of endogenous adenosine, by determining the effect of caffeine, a non-selective adenosine A(1) and A(2) receptor antagonist, on its actions."	3.71	Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: multiple interactions. ( Allen, GV; Chase, T; Esser, MJ; Sawynok, J, 2001)
"Recent studies suggest an association between caffeine consumption and tremor."	3.71	Effect of acute caffeine on severity of harmaline induced tremor in rats. ( Al-Deeb, S; Al-Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2002)
"The present study extended the previous studies to determine the effects of acute and repeated administration of caffeine, a non-specific phosphodiesterase (PDE) inhibitor and pentoxyfylline, a specific type-4 phosphodiesterase (PDE4) inhibitor on (1) baseline anxiety-like behavior and (2) the response to an acute challenge with diazepam on anxiety-like behavior in the hole-board test."	3.70	Effects of acute and repeated dose administration of caffeine and pentoxifylline on diazepam-induced mouse behavior in the hole-board test. ( Campos, AR; Paula, WG; Rao, VS; Santos, FA; Silva, RM, 1999)
"Caffeine potentiation of ketorolac-induced antinociception in the pain-induced functional impairment model in rats was assessed."	3.70	Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia. ( Aguirre-Bañuelos, P; Castañeda-Hernández, G; Granados-Soto, V; López-Muñoz, FJ, 1999)
"In the present study, we sought to determine whether administration of caffeine, a non-selective adenosine receptor antagonist, would affect the thermal antihyperalgesic efficacy of acute amitriptyline in a rat model of neuropathic pain."	3.70	Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. ( Esser, MJ; Sawynok, J, 2000)
"Despite significant progress in understanding of the potential of adenosine A1 receptor-based therapies in treatment of cerebral ischemia and stroke, very little is known about the effect of selective stimulation of adenosine A2A receptors on the outcome of a cerebrovascular arrest."	3.69	Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. ( Jacobson, KA; Lin, RC; Von Lubitz, DK, 1995)
"The inherited disease Lesch-Nyhan syndrome, which is caused by a deficiency of the enzyme hypoxanthine phosphoribosyltransferase (HPRT), is characterized by behavioural alterations, including self-injurious behaviour and mental retardation."	3.68	Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. ( Melton, DW; Wu, CL, 1993)
"Rats ingesting high doses of caffeine reproduce the self-destructive behaviour observed in the Lesch-Nyhan syndrome."	3.67	Lesch-Nyhan syndrome, caffeine model: increase of purine and pyrimidine enzymes in rat brain. ( Grisolía, S; Jordá, A; Miñana, MD; Portolés, M, 1984)
"Caffeine treatment increases attention and improves learning, memory, and olfactory discrimination without altering blood pressure and body weight."	2.82	Effects of Caffeine Consumption on Attention Deficit Hyperactivity Disorder (ADHD) Treatment: A Systematic Review of Animal Studies. ( López Palomé, J; Martin de la Torre, O; Redolar-Ripoll, D; Vázquez, JC, 2022)
"Insomnia is a common and disabling complaint for which there is a need for improved treatments."	2.73	A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2007)
"Caffeine is a most widely consumed physiological stimulant worldwide, which is consumed via natural sources, such as coffee and tea, and now marketed sources such as energy drinks and other dietary supplements."	2.53	Caffeine and cardiovascular diseases: critical review of current research. ( Hayes, A; Klimas, J; Kobyliak, N; Kruzliak, P; Kubatka, P; La Rocca, G; Loftus, H; Novak, J; Pohanka, M; Qaradakhi, T; Smith, RM; Soucek, M; Uehara, Y; Zagatina, A; Zulli, A, 2016)
"The pathophysiology of obesity and type 2 diabetes as well as the necessity of preventive options based on the increasing prevalence of these two disorders worldwide is briefly discussed."	2.53	Coffee consumption, obesity and type 2 diabetes: a mini-review. ( Lima, DR; Santos, RM, 2016)
"Current drug treatments for obesity produce small and usually unsustainable decreases in body weight with the risk of major adverse effects."	2.52	Functional foods as potential therapeutic options for metabolic syndrome. ( Brown, L; Panchal, SK; Poudyal, H, 2015)
"Sporadic Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases and as such they represent major public health problems."	2.46	Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. ( Chen, X; Geiger, JD; Ghribi, O, 2010)
" We believe that the cognitive benefits of chronic caffeine administration in AD mice are due to caffeine itself, and not metabolites of caffeine; this, because our long-term administration of theophylline to AD mice provided no cognitive benefits."	2.46	Caffeine and coffee as therapeutics against Alzheimer's disease. ( Arendash, GW; Cao, C, 2010)
"3."	2.41	The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. ( Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S, 2002)
"Obesity is characterised by pathophysiological defects affecting both sides of the energy balance equation."	2.40	What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. ( Astrup, A; Lundsgaard, C, 1998)
"Parkinson's disease is both a motor and non-motor disorder."	1.91	Rotenone induced olfactory deficit in Parkinson's disease rat model: The protective role of adenosine A ( Adeyeye, TA; Babatunde, BR; Johnson, VF; Shallie, PD, 2023)
" However, long-term administration of this approach is linked to several complications, and a definitive gold-standard therapy for PD is yet to be identified."	1.91	Caffeine alleviates anxiety-like behavior and brainstem lesions in a rotenone-induced rat model of Parkinson's disease. ( Adeyeye, TA; Babatunde, BR; Ehireme, SE; Shallie, PD, 2023)
"Caffeine has been reported for its antiinflammatory properties by stimulating phagocytosis."	1.72	Antiinflammatory and antiinfective effect of caffeine in a mouse model of disseminated salmonellosis. ( da Silva Júnior, VA; de Almeida, IA; de Souza Silva, E; de Souza, JKU; Dorvigny, BM; Lima-Filho, JV; Santana, LN; Soares, AF; Tavares, LS, 2022)
"Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy."	1.72	Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022)
"Prostate cancer was induced in rats with methylnitrosourea and testosterone and tumor incidence was determined."	1.72	Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model. ( Bosland, MC; Condon, MS; Horton, L, 2022)
"In the caffeine-induced insomnia model, the administration of a Saaz-Saphir mixture increased the sleep time compared to Saaz or Saphir administration alone, which was attributed to the increase in NREM sleep time by the δ-wave increase."	1.62	GABA ( Ahn, Y; Cho, HJ; Jo, K; Kwak, WK; Min, B; Suh, HJ, 2021)
"Caffeine is a common stimulant widely existed in food and has stimulatory effects on the central nervous system, shift-work individuals often rely on caffeine to maintain attention and keep awake."	1.62	Caffeine-related effects on cognitive performance: Roles of apoptosis in rat hippocampus following sleep deprivation. ( Huang, P; Huang, X; Li, H; Wang, P; Xie, G, 2021)
"Tramadol (TR) is an analgesic drug used to treat moderate-to-severe pain but it induces seizure even at therapeutic doses."	1.62	Caffeine attenuates seizure and brain mitochondrial disruption induced by Tramadol: the role of adenosinergic pathway. ( Ahangar, N; Bameri, B; Fallah, M; Mohammadi, H; Samadi, M; Shaki, F, 2021)
"Caffeine has been known to combat stress-evoked depression."	1.56	New insights into the effects of caffeine on adult hippocampal neurogenesis in stressed mice: Inhibition of CORT-induced microglia activation. ( He, RR; Kurihara, H; Li, WX; Li, YF; Luo, Z; Mao, ZF; Ouyang, SH; Tu, LF; Wang, GE; Wu, YP; Zhang, QY, 2020)
"Caffeine-treated and -untreated pups underwent the Vannucci procedure (unilateral carotid ligation, global hypoxia) on P2."	1.56	Caffeine Restores Background EEG Activity Independent of Infarct Reduction after Neonatal Hypoxic Ischemic Brain Injury. ( Gonzalez, F; McQuillen, PS; Sun, H, 2020)
"Treatment with caffeine significantly attenuated changes in hyperoxia-induced cell death and apoptosis-associated factors."	1.56	Prevention of Oxygen-Induced Inflammatory Lung Injury by Caffeine in Neonatal Rats. ( Bendix, I; Bührer, C; Endesfelder, S; Schmitz, T; Strauß, E, 2020)
"Caffeine is a substance that is consumed worldwide, and it may exert neuroprotective effects against various cerebral insults, including neurotrauma, which is the most prevalent injury among military personnel."	1.51	Caffeine attenuates brain injury but increases mortality induced by high-intensity blast wave exposure. ( Chen, JF; Chen, X; Li, P; Liu, D; Ning, YL; Peng, Y; Tian, HK; Wang, ZG; Yang, N; Zhang, XZ; Zhao, Y; Zhao, ZA; Zhou, YG, 2019)
"Amyloid-β, one of the hallmarks of Alzheimer's disease (AD), is toxic to neurons and can also cause brain cell death."	1.51	Ingredients in Zijuan Pu'er Tea Extract Alleviate β-Amyloid Peptide Toxicity in a ( Bai, S; Du, F; Fu, X; Jiao, Y; Ma, J; Wang, L; Zhou, L, 2019)
"Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation and growth, leading to end-stage renal disease."	1.51	Caffeine Accelerates Cystic Kidney Disease in a Pkd1-Deficient Mouse Model. ( Balbo, BE; Fonseca, JM; Heilberg, IP; Iannuzzi, LR; Meca, R; Onuchic, LF; Ormanji, MS; Santana Costa, E, 2019)
"In a C."	1.48	Coffee extract and caffeine enhance the heat shock response and promote proteostasis in an HSF-1-dependent manner in Caenorhabditis elegans. ( Brunquell, J; Morris, S; Snyder, A; Westerheide, SD, 2018)
"Caffeine treatment significantly decreased the elevated serum ALT, AST, and bilirubin and increased the reduced albumin level."	1.48	Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention. ( Ayoub, SE; Elkashefand, WF; Helal, MG; Ibrahim, TM, 2018)
"It is associated with allodynia and hyperalgesia."	1.48	Neurobiological mechanisms of antiallodynic effect of transcranial direct current stimulation (tDCS) in a mice model of neuropathic pain. ( Caumo, W; Dos Santos, ARS; Martins, DF; Martins, TC; Medeiros, LF; Nucci-Martins, C; Siteneski, A; Souza, A; Torres, ILS, 2018)
"The caffeine (10 mg/kg) was administered by gavage route, once daily, during 7 or 14 consecutive days to investigate the effects of acute or subchronic caffeine treatment on long-term behavioural and cognitive deficits induced by CLP."	1.48	Effects of Caffeine on Behavioural and Cognitive Deficits in Rats. ( Assis, MS; Boëchat-Barros, R; Carneiro, FP; Eudes-Filho, J; Faro, LRF; Ferreira, VM; Lima, NT; Marchiori, S; Motoyama, AB; Silva, MV; Soares, AC; Sousa, DN; Souza, GMR, 2018)
"Fibrosis was assessed by measuring the liver hydroxyproline content."	1.46	Coffee consumption prevents fibrosis in a rat model that mimics secondary biliary cirrhosis in humans. ( Arauz, J; Favari, L; Galicia-Moreno, M; Hernández-Aquino, E; Muriel, P; Segovia, J; Zarco, N, 2017)
" Here we investigated the effects of chronic administration of caffeine (5mg/kg, twice daily for 14days) and its withdrawal on day 15th on the activity of per se ineffective doses of fluoxetine (5mg/kg) and escitalopram (2mg/kg) given on day 15th."	1.46	Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. ( Doboszewska, U; Dudka, J; Herbet, M; Kanadys, A; Korga, A; Ostrowska, M; Poleszak, E; Serefko, A; Świąder, K; Szopa, A; Terlecka, J; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A; Wyska, E, 2017)
"Both caffeine pretreatments in chronic stressed rats, and chronic caffeine in acute stressed ones reduced the elevated myeloperoxidase activities (p<0."	1.46	Protective effect of low dose caffeine on psychological stress and cognitive function. ( Akakın, D; Ellek, N; Hamamcı, R; Kasimay Cakir, O; Kayalı, DG; Keleş, H; Özbeyli, D; Salehin, N; Yüksel, M, 2017)
"Machado-Joseph disease (MJD) is a neurodegenerative spinocerebellar ataxia (SCA) associated with an expanded polyglutamine tract within ataxin-3 for which there is currently no available therapy."	1.46	Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia. ( Cunha, RA; Gonçalves, N; Hirai, H; Pereira de Almeida, L; Prediger, RD; Simões, AT, 2017)
"Caffeine treatment significantly improves outcome when compared to phosphate buffered saline."	1.46	Single Dose Caffeine Protects the Neonatal Mouse Brain against Hypoxia Ischemia. ( Ådén, U; Fredholm, BB; Urmaliya, V; Winerdal, M; Winerdal, ME; Winqvist, O, 2017)
"Co-treatment with caffeine and TAA restored normal liver structure and function."	1.46	Caffeine intake decreases oxidative stress and inflammatory biomarkers in experimental liver diseases induced by thioacetamide: Biochemical and histological study. ( Amer, MG; Mazen, NF; Mohamed, AM, 2017)
"AIF at the dosage of 50 mg/mL, effectively attenuated caffeine-induced wakefulness (P<0."	1.43	Hypnotic effects of a novel anti-insomnia formula on Drosophila insomnia model. ( Chan, EH; Fung, KP; Ko, CH; Koon, CM; Lau, CB; Lee, KY; Leung, PC; Wing, YK; Yu, SL, 2016)
"Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity."	1.43	Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016)
"Caffeine is able to increase the effect of rac-Flur in the arthritic gout-type pain in rats."	1.43	Antinociceptive Effect of Racemic Flurbiprofen and Caffeine Co-Administration in an Arthritic Gout-Type Pain in Rats. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; Liévano-Reyes, R; López-Muñoz, FJ; Pérez-Méndez, HI; Solís-Oba, A, 2016)
"Caffeine, which is an antagonist of adenosine receptors, is the most widely consumed psychoactive drug in the world."	1.43	Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma. ( Agudo-Barriuso, M; Ambrósio, AF; Madeira, MH; Nadal-Nícolas, F; Ortin-Martinez, A; Santiago, AR; Vidal-Sanz, M, 2016)
"Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine."	1.42	Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. ( Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B, 2015)
"Levetiracetam is an antiepileptic drug with analgesic efficacy shown in pain models and small clinical trials."	1.42	The effects of levetiracetam, sumatriptan, and caffeine in a rat model of trigeminal pain: interactions in 2-component combinations. ( Micov, AM; Pecikoza, UB; Popović, BV; Stepanović-Petrović, RM; Tomić, MA, 2015)
" These results suggest that caffeine exposure can at first be benign, but that high dosage or prolonged exposure hinders functional recovery."	1.42	Time-dependent bidirectional effects of chronic caffeine on functional recovery of the dorsal light reflex after hemilabyrinthectomy in the goldfish Carassius auratus. ( Brockhoff, BL; Goodson, NB; Huston, JP; Spieler, RE, 2015)
"d-galactose has been considered a senescent model for age-related neurodegenerative disease."	1.42	Caffeine prevents d-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. ( Ali, T; Kim, MO; Ullah, F; Ullah, N, 2015)
"Caffeine treatment prevented the SD induced down-regulation of synaptophysin and synapsin I proteins with no change in PSD-95 protein in hippocampus."	1.42	Caffeine and modafinil given during 48 h sleep deprivation modulate object recognition memory and synaptic proteins in the hippocampus of the rat. ( Kauser, H; Kumari, P; Panjwani, U; Ray, K; Sahu, S; Wadhwa, M, 2015)
"Mice were tested for tactile mechanical hyperalgesia at 1, 2, and 3 weeks following procedures."	1.42	Caffeine prevents antihyperalgesic effect of gabapentin in an animal model of CRPS-I: evidence for the involvement of spinal adenosine A1 receptor. ( Batisti, AP; Daruge-Neto, E; Emer, AA; Martins, DF; Mazzardo-Martins, L; Piovezan, AP; Prado, MR; Santos, AR, 2015)
"Caffeine treatment resulted in the recovery of fructose-induced decrease in nitric oxide production in the NTS."	1.40	Caffeine intake improves fructose-induced hypertension and insulin resistance by enhancing central insulin signaling. ( Chen, BR; Cheng, PW; Cheng, WH; Ho, WY; Liou, JC; Liu, CP; Lu, PJ; Sun, GC; Tseng, CJ; Yeh, TC, 2014)
"Caffeine displays a broad array of actions on the brain."	1.40	Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury. ( Daglioglu, YK; Erdogan, S; Kilicdag, H; Zorludemir, S, 2014)
"Tau pathology found in Alzheimer's disease (AD) is crucial in cognitive decline."	1.40	Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. ( Blum, D; Buée, L; Carrier, S; Demeyer, D; Derisbourg, M; Eddarkaoui, S; Hamdane, M; Laurent, C; Leboucher, A; Müller, CE; Schneider, M, 2014)
"Addiction and substance abuse are found ubiquitously throughout human society."	1.40	Zebrafish and conditioned place preference: a translational model of drug reward. ( Caramillo, EM; Collier, AD; Echevarria, DJ; Khan, KM; Mohn, RS, 2014)
"Caffeine was added to a 20% alcohol solution via DID."	1.40	"Wired," yet intoxicated: modeling binge caffeine and alcohol co-consumption in the mouse. ( Boehm, SL; Companion, M; Fritz, BM, 2014)
"Hypertension is often associated with skeletal muscle pathological conditions related to function and metabolism."	1.40	Calcium homeostasis is altered in skeletal muscle of spontaneously hypertensive rats: cytofluorimetric and gene expression analysis. ( Camerino, GM; Cannone, M; Conte Camerino, D; Conte, E; De Bellis, M; Fraysse, B; Liantonio, A; Pierno, S; Scaramuzzi, A; Tricarico, D, 2014)
"Caffeine (1g/L) was applied through the drinking water."	1.39	Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. ( Cunha, RA; de Almeida, LP; Gonçalves, N; Simões, AT, 2013)
"5 mg/day doses of caffeine significantly increased memory capability and the expression of hippocampal BDNF and TrkB in PS1/APP mice with a dose-response effect."	1.39	Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease. ( Han, K; Jia, N; Li, J; Min, LQ; Yang, L, 2013)
"Caffeine treatment at a daily dose of 10 and/or 20 mg/kg, sc was executed during postnatal days 7-11."	1.39	Different effects of postnatal caffeine treatment on two pentylenetetrazole-induced seizure models persist into adulthood. ( Kubová, H; Mareš, P; Tchekalarova, JD, 2013)
"The adenosinergic system was assessed by systemic (intraperitoneal), central (intrathecal), and peripheral (intraplantar) administration of caffeine."	1.39	Ankle joint mobilization affects postoperative pain through peripheral and central adenosine A1 receptors. ( Cidral-Filho, FJ; Martins, DF; Mazzardo-Martins, L; Santos, AR; Stramosk, J, 2013)
"Caffeine is a nonselective adenosine receptor antagonist; chronic consumption has proved protective toward neurodegenerative diseases such as Parkinson's and Alzheimer's diseases."	1.39	Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. ( Armida, M; Ferrante, A; Matteucci, A; Pèzzola, A; Popoli, P; Potenza, RL; Puopolo, M, 2013)
"Withdrawal of caffeine however produced memory deficits and significantly increases the immobility time of rats in FST."	1.38	Altered brain serotonergic neurotransmission following caffeine withdrawal produces behavioral deficits in rats. ( Haider, S; Haleem, DJ; Khaliq, S; Naqvi, F; Perveen, T; Saleem, S, 2012)
"During drug development, seizure threshold tests are widely used to identify potential proconvulsant activity of investigational drugs."	1.38	Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models. ( Bankstahl, JP; Bankstahl, M; Bloms-Funke, P; Löscher, W, 2012)
"In the brains of patients with fetal Minamata disease (FMD), which is caused by exposure to methylmercury (MeHg) during development, many neurons are hypoplastic, ectopic, and disoriented, indicating disrupted migration, maturation, and growth."	1.38	Rescue of neuronal migration deficits in a mouse model of fetal Minamata disease by increasing neuronal Ca2+ spike frequency. ( Fahrion, JK; Galas, L; Komuro, H; Komuro, Y; Li, Y; Littner, Y; Ohno, N; Raoult, E; Vaudry, D, 2012)
"Caffeine treatment increased the percentage of mitotic tumor cells undergoing apoptosis (lethal mitosis) whereas RW inhibited the increase in interleukin-6 that occurred during the progression of LNCaP tumors from androgen dependence to androgen independence."	1.38	Inhibition of progression of androgen-dependent prostate LNCaP tumors to androgen independence in SCID mice by oral caffeine and voluntary exercise. ( Conney, AH; Cui, XX; Huang, MT; Lee, MJ; Lin, Y; Liu, Y; Shih, WJ; Wagner, GC; Yang, CS; Zheng, X, 2012)
"Nowadays the pharmacological treatment of the attention deficit hyperactivity disorder (ADHD) is based on amphetamine derivatives (i."	1.37	Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD). ( Ahern, S; Caballero, M; Carbonell, L; Ciruela, F; Cuffí, ML; Fernández-Dueñas, V; Núñez, F; Sánchez, S, 2011)
"Caffeine treatment stimulated PKA activity, increased phospho-CREB levels, and decreased phospho-JNK and phospho-ERK expression in the striatum of APPswe mice, all of which are thought to be beneficial changes for brain function."	1.37	Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. ( Arendash, GW; Burgess, S; Echeverria, V; Patel, S; Zeitlin, R, 2011)
"Pre-treatment with dantrolene protected YAC128 MSNs from glutamate excitotoxicty, with an effective concentration of 100 nM and above."	1.37	Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. ( Bezprozvanny, I; Chen, X; Herndon, E; Lvovskaya, S; Supnet, C; Wu, J, 2011)
"Caffeine (10 mg/kg) pretreatment with venlfaxine (5 mg/kg) did not produce any significant effect on locomotor activity, immobility period and oxidative damage as compared to their effect per se."	1.36	Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. ( Garg, R; Gaur, V; Kumar, A; Kumar, P, 2010)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by a single point mutation in a well-defined region of the cardiac type 2 ryanodine receptor (RyR)2."	1.36	Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. ( Doi, M; Ikeda, Y; Ikemoto, N; Kobayashi, S; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Ono, M; Suetomi, T; Tateishi, H; Uchinoumi, H; Xu, X; Yamamoto, T; Yano, M, 2010)
" Using a bivascular liver perfusion dose-response curves to adenosine of the HA were performed in the presence and the absence of pan-adenosine blocker (8-SPT), A1 blocker (caffeine) or nitric oxide synthase-blocker (l-NMMA) after preconstriction with an alpha1-agonist (methoxamine)."	1.36	A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl-cirrhotic liver. ( Groszmann, RJ; Mehal, WZ; Ripoll, C; Zipprich, A, 2010)
"Caffeine has antioxidant properties and has been demonstrated to reduce Abeta levels in transgenic mouse models of familial AD."	1.36	Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. ( Chen, X; Dasari, B; Geiger, JD; Ghribi, O; Larson, T; Marwarha, G; Prasanthi, JR, 2010)
"Treatment with caffeine for 7 to 10 days in a mouse-model improved endothelial repair after denudation of the carotid artery."	1.35	Caffeine enhances endothelial repair by an AMPK-dependent mechanism. ( Dimmeler, S; Fichtlscherer, S; Fisslthaler, B; Haendeler, J; Liehn, EA; Popp, R; Spyridopoulos, I; Toennes, SW; Trepels, T; Weber, C; Zeiher, AM; Zernecke, A, 2008)
"Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS)."	1.35	Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. ( Barodia, SK; Luthra, PM; Raghubir, R, 2009)
" Following recovery, animals were dosed with caffeine (10 mg/kg) alone or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg)."	1.35	Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2009)
" The findings of current in vitro studies now suggest that bactericidal concentrations of SCC1 are not toxic to airway epithelial cells in primary culture."	1.35	In vitro and murine efficacy and toxicity studies of nebulized SCC1, a methylated caffeine-silver(I) complex, for treatment of pulmonary infections. ( Brody, SL; Cannon, CL; Capps, GH; Hindi, KM; Hogue, LA; Ibricevic, A; Kascatan-Nebioglu, A; Vajravelu, RK; Walter, MJ; Youngs, WJ, 2009)
"This type of seizures never appeared in caffeine-treated 25-day-old animals."	1.35	Postnatal caffeine treatment affects differently two pentylenetetrazol seizure models in rats. ( Kubová, H; Mares, P; Tchekalarova, J, 2009)
"We have recently shown that Alzheimer's disease (AD) transgenic mice given a moderate level of caffeine intake (the human equivalent of 5 cups of coffee per day) are protected from development of otherwise certain cognitive impairment and have decreased hippocampal amyloid-beta (Abeta) levels due to suppression of both beta-secretase (BACE1) and presenilin 1 (PS1)/gamma-secretase expression."	1.35	Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. ( Arendash, GW; Cao, C; Citron, BA; Dickson, A; Echeverria, V; Lin, X; Mamcarz, M; Mori, T; Potter, H; Rezai-Zadeh, K; Runfeldt, M; Tane, J, 2009)
"Caffeine is a nonspecific adenosine receptor blocker, and thus drinking CC may block the myocardial protective effects of statins."	1.35	Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat. ( Abu Said, GH; Birnbaum, Y; Hughes, MG; Lin, Y; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Ye, Y, 2008)
"Melatonin was tested in two experimental groups, one of which underwent common bile duct ligation for 2 days and another that was later de-ligated for 2 days."	1.35	Protective effect of melatonin on Ca2+ homeostasis and contractility in acute cholecystitis. ( Camello, PJ; Gomez-Pinilla, PJ; Pozo, MJ, 2008)
"Nicotine or caffeine-treated animals showed significant restoration against most of the MPTP-induced alterations."	1.35	Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse. ( Nath, C; Patel, DK; Patel, S; Singh, C; Singh, K; Singh, MP; Singh, S, 2008)
"Occurrence of seizures following long-term oral administration of caffeine (0."	1.35	Evidence for the involvement of the adenosine A(2A) receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine. ( Costentin, J; El Yacoubi, M; Ledent, C; Parmentier, M; Vaugeois, JM, 2008)
"Some DMD patients show a dilated cardiomyopathy leading to heart failure."	1.34	Intracellular calcium handling in ventricular myocytes from mdx mice. ( Allen, DG; Williams, IA, 2007)
"Cizolirtine-induced antihyperalgesia was compared before and after pretreatment with ADO A(1)-A(2A) and 5-HT(1B/1D) receptor ligands in rats rendered diabetic by streptozotocin pretreatment and suffering from neuropathic pain."	1.34	Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. ( Aubel, B; Bourgoin, S; Farré, A; Hamon, M; Kayser, V, 2007)
"Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by adrenergically mediated polymorphic ventricular tachycardia leading to syncope and sudden cardiac death."	1.33	Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. ( Cerrone, M; Colombi, B; di Barletta, MR; Napolitano, C; Priori, SG; Santoro, M; Scelsi, M; Villani, L, 2005)
"The brains of fetal alcohol syndrome patients exhibit impaired neuronal migration, but little is known about the mechanisms underlying this abnormality."	1.33	Reversal of neuronal migration in a mouse model of fetal alcohol syndrome by controlling second-messenger signalings. ( Komuro, H; Kumada, T; Lakshmana, MK, 2006)
"Caffeine is a mixed adenosine receptor antagonist, therefore its effects could be due to a different action on adenosine receptor subtypes; an additional mechanism of action cannot be excluded."	1.33	Biphasic effect of chronic postnatal caffeine treatment on cortical epileptic afterdischarges during ontogeny in rats. ( Kubová, H; Mares, P; Tchekalarova, J, 2006)
" The antinociceptive efficacies were evaluated using several dose-response curves and time courses."	1.33	Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats. ( Bravo, G; Cook, HJ; Déciga-Campos, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López, JR; López-Muñoz, FJ, 2006)
"When caffeine was administered prior to MDMA, a potentiation of locomotor activity was observed, which consisted in an increase in maximal values and in a prolonged time of activity."	1.33	Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. ( Camarasa, J; Escubedo, E; Pubill, D, 2006)
"When caffeine and adenosine were co-administered, there was no synergistic effect, possibly due to mutual antagonistic effects."	1.33	Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2006)
"Caffeine is a receptor antagonist for adenosine that might interfere with the neuroprotective effect of adenosine in ischemic-hypoxic conditions."	1.32	Caffeine impairs short-term neurological outcome after concussive head injury in rats. ( Ahmad Khan, H; Al Deeb, S; Al Moutaery, K; Tariq, M, 2003)
"Caffeine treatment augmented A1AR expression on microglia, with ensuing reduction of EAE severity, which was further enhanced by concomitant treatment with the A1AR agonist, adenosine amine congener."	1.32	A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. ( Henry, S; Noorbakhsh, F; Power, C; Schnermann, J; Tsutsui, S; Warren, K; Winston, BW; Yong, VW, 2004)
"Trihexyphenidyl (THP) is a drug commonly used to reduce parkinsonian symptoms."	1.32	Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats. ( Alvarez-Cervera, F; Arankowsky-Sandoval, G; Góngora-Alfaro, JL; Moo-Puc, RE; Villanueva-Toledo, J, 2004)
"Sumatriptan was not able to reverse either the kainic acid-induced or the NMDA-induced hyperalgesia."	1.32	Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. ( Galeotti, N; Ghelardini, C; Grazioli, I; Uslenghi, C, 2004)
"Psychosis frequently occurs in Alzheimer's disease (AD), being associated with more severe cognitive decline, but the underlying mechanisms are unknown."	1.32	Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine. ( da Silva, AL; Dall'Igna, OP; Hoffmann, A; Lara, DR; Souza, DO, 2004)
"The role of morphine-dependence on the seizure susceptibility has been evaluated with models of pentylenetetrazol (PTZ)-kindling and acute convulsions induced by PTZ, N-methyl-D-aspartic acid (NMDA), picrotoxin and caffeine in adult male rats."	1.31	Chemical kindling and seizure susceptibility in morphine dependent rats. ( Atapour, N; Kalantaripour, TP; Niazi, M; Nourpanah, M, 2000)
"Ventricular arrhythmias and contractile dysfunction are the main causes of death in human heart failure (HF)."	1.31	Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. ( Bers, DM; Li, L; Pogwizd, SM; Schlotthauer, K; Yuan, W, 2001)
"Caffeine (10 mM) was used to release calcium from the SR."	1.30	Effects of cyclic adenosine monophosphate (cAMP) on sarcoplasmic reticulum Ca(2+)-loading in failing rabbit and human cardiac trabeculae. ( Cobbe, SM; Denvir, MA; MacFarlane, NG; Miller, DJ, 1998)
"Treatment with ramipril reduced blood pressure and force development in response to Bay K8644 in adult SHRSP, although not to levels of WKY rats, whereas WKY rats were unaffected by treatment."	1.29	Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats. ( Traub, O; Webb, RC, 1993)
"Caffeine treatment at the dose 10 mg/kg b."	1.28	Validation of aversion towards open space and height as a measure of anxiety in the genetically based animal model of depression. ( Golda, V; Petr, R, 1990)
" This finding suggests that the intestinal absorption of calcium was stimulated by the increase in 1,25(OH)2D production after chronic administration of caffeine."	1.27	Differential effect of caffeine administration on calcium and vitamin D metabolism in young and adult rats. ( Aloia, JF; Yeh, JK, 1986)
"This model for malignant hyperpyrexia resembles the naturally occurring disease more closely than several preceding pharmacologic models."	1.26	A laboratory animal model for malignant hyperpyrexia. ( Durbin, CG; Rosenberg, H, 1979)
"In this Research Conference we define malignant hyperthermia, present its brief history, and describe the diagnostic procedures and directions of research in our laboratory."	1.26	Malignant hyperthermia: diagnosis, treatment and investigations of a skeletal muscle lesion. ( Flewellen, EH; Nelson, TE, 1979)

Research

Studies (371)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Length of Time From Extubation to Discharge From Postanesthesia Recovery Unit

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (5.12)	18.7374
1990's	24 (6.47)	18.2507
2000's	119 (32.08)	29.6817
2010's	166 (44.74)	24.3611
2020's	43 (11.59)	2.80

Authors	Studies
Palanki, MS	1
Erdman, PE	1
Ren, M	1
Suto, M	1
Bennett, BL	1
Manning, A	1
Ransone, L	1
Spooner, C	1
Desai, S	1
Ow, A	1
Totsuka, R	1
Tsao, P	1
Toriumi, W	1
Drabczyńska, A	1
Müller, CE	3
Schiedel, A	1
Schumacher, B	1
Karolak-Wojciechowska, J	1
Fruziński, A	1
Zobnina, W	1
Yuzlenko, O	1
Kieć-Kononowicz, K	1
Avdeef, A	1
Tam, KY	1
Redondo, M	1
Zarruk, JG	1
Ceballos, P	1
Pérez, DI	1
Pérez, C	1
Perez-Castillo, A	1
Moro, MA	1
Brea, J	1
Val, C	1
Cadavid, MI	1
Loza, MI	1
Campillo, NE	1
Martínez, A	1
Gil, C	1
Solinski, HJ	1
Dranchak, P	1
Oliphant, E	1
Gu, X	1
Earnest, TW	1
Braisted, J	1
Inglese, J	1
Hoon, MA	1
Abrams, RPM	1
Yasgar, A	1
Teramoto, T	1
Lee, MH	1
Dorjsuren, D	1
Eastman, RT	1
Malik, N	1
Zakharov, AV	1
Li, W	3
Bachani, M	1
Brimacombe, K	1
Steiner, JP	1
Hall, MD	1
Balasubramanian, A	1
Jadhav, A	1
Padmanabhan, R	1
Simeonov, A	1
Nath, A	1
de Alcântara Almeida, I	1
Mancebo Dorvigny, B	1
Souza Tavares, L	1
Nunes Santana, L	1
Vitor Lima-Filho, J	1
Min, B	1
Ahn, Y	1
Cho, HJ	1
Kwak, WK	1
Suh, HJ	1
Jo, K	1
Dorvigny, BM	1
Tavares, LS	1
de Almeida, IA	1
Santana, LN	1
de Souza Silva, E	1
de Souza, JKU	1
Soares, AF	1
da Silva Júnior, VA	1
Lima-Filho, JV	1
Szczepkowska, A	1
Wójcik, M	1
Tomaszewska-Zaremba, D	1
Antushevich, H	1
Krawczyńska, A	1
Wiechetek, W	1
Skipor, J	1
Herman, AP	1
Chwedorowicz, R	4
Łukawski, K	4
Raszewski, G	4
Czuczwar, SJ	5
Vázquez, JC	1
Martin de la Torre, O	1
López Palomé, J	1
Redolar-Ripoll, D	1
Gomaa, AA	1
Farghaly, HSM	1
Ahmed, AM	1
El-Mokhtar, MA	1
Hemida, FK	1
Yang, L	2
Yu, X	1
Zhang, Y	2
Liu, N	1
Li, D	1
Xue, X	1
Fu, J	1
Bosland, MC	1
Horton, L	1
Condon, MS	1
Markova, EV	1
Knyazheva, MA	1
Tikhonova, MA	1
Amstislavskaya, TG	1
Fontana, BD	1
Parker, MO	1
Kakiyama, G	1
Minowa, K	1
Rodriguez-Agudo, D	1
Martin, R	1
Takei, H	1
Mitamura, K	1
Ikegawa, S	1
Suzuki, M	1
Nittono, H	1
Fuchs, M	1
Heuman, DM	1
Zhou, H	2
Pandak, WM	1
Raoofi, A	1
Rezaie, MJ	1
Delbari, A	1
Ghoreishi, SA	1
Sichani, PH	1
Maleki, S	1
Nasiry, D	1
Akhlaghi, M	1
Ebrahimi, V	1
Khaneghah, AM	1
Babatunde, BR	2
Adeyeye, TA	2
Johnson, VF	1
Shallie, PD	2
Rei, N	2
Valente, CA	2
Vaz, SH	2
Farinha-Ferreira, M	2
Ribeiro, JA	2
Sebastião, AM	2
Stazi, M	1
Zampar, S	1
Klafki, HW	1
Meyer, T	1
Wirths, O	1
Sabir, H	1
Maes, E	1
Zweyer, M	1
Schleehuber, Y	1
Imam, FB	1
Silverman, J	1
White, Y	1
Pang, R	1
Pasca, AM	1
Robertson, NJ	1
Maltepe, E	1
Bernis, ME	1
Clayman, CL	1
Hwang, C	1
Connaughton, VP	1
Ehireme, SE	1
Wren, LM	1
DeKeyser, JM	1
Barefield, DY	1
Hawkins, NA	1
McNally, EM	1
Kearney, JA	1
Wasserstrom, JA	1
George, AL	1
Higuchi, T	1
Oshiro, H	1
Miyake, K	1
Sugisawa, N	1
Han, Q	1
Tan, Y	1
Park, J	1
Zhang, Z	1
Razmjooei, S	1
Yamamoto, N	1
Hayashi, K	1
Kimura, H	1
Miwa, S	1
Igarashi, K	1
Bouvet, M	1
Chawla, SP	1
Singh, SR	1
Tsuchiya, H	1
Hoffman, RM	1
Alves, CB	1
Almeida, AS	1
Marques, DM	1
Faé, AHL	1
Machado, ACL	1
Oliveira, DL	1
Portela, LVC	1
Porciúncula, LO	4
de Carvalho, TS	1
Cardoso, PB	1
Santos-Silva, M	1
Lima-Bastos, S	1
Luz, WL	1
Assad, N	1
Kauffmann, N	1
Passos, A	1
Brasil, A	1
Bahia, CP	1
Moraes, S	1
Gouveia, A	1
de Jesus Oliveira Batista, E	1
Oliveira, KRMH	1
Herculano, AM	1
Van der Veeken, L	1
Grönlund, S	1
Gerdtsson, E	1
Holmqvist, B	1
Deprest, J	1
Ley, D	1
Bruschettini, M	1
Zheng, J	1
Yang, M	1
Song, S	1
Dai, Q	1
Ji, G	1
Zhou, Z	1
Ramos, AC	1
de Mattos Hungria, F	1
Camerini, BA	1
Suiama, MA	1
Calzavara, MB	1
Mitra, S	2
Santana Miranda, V	1
McMillan, C	1
Dykes, D	1
Mucha, M	1
Marth, TE	1
Poe, B	1
Basu, DG	1
Bult-Ito, A	1
Iriventi, P	1
Gupta, NV	1
Osmani, RAM	1
Balamuralidhara, V	1
Chen, S	2
Wu, Q	1
Zhong, D	1
Li, C	3
Du, L	1
Mao, ZF	1
Ouyang, SH	1
Zhang, QY	1
Wu, YP	1
Wang, GE	1
Tu, LF	1
Luo, Z	1
Li, WX	1
Kurihara, H	1
Li, YF	1
He, RR	1
França, AP	1
Schamne, MG	1
de Souza, BS	1
da Luz Scheffer, D	1
Bernardelli, AK	1
Corrêa, T	1
de Souza Izídio, G	1
Latini, A	1
da Silva-Santos, JE	1
Canas, PM	1
Cunha, RA	8
Prediger, RD	6
Jing, N	1
Liu, X	3
Jin, M	1
Yang, X	1
Hu, X	1
Zhao, K	1
Sun, H	1
Gonzalez, F	1
McQuillen, PS	1
Endesfelder, S	2
Strauß, E	2
Bendix, I	1
Schmitz, T	2
Bührer, C	2
Velázquez, AM	1
Roglans, N	1
Bentanachs, R	1
Gené, M	1
Sala-Vila, A	1
Lázaro, I	1
Rodríguez-Morató, J	1
Sánchez, RM	1
Laguna, JC	1
Alegret, M	1
Xie, G	1
Huang, X	1
Li, H	1
Wang, P	1
Huang, P	1
Chen, JF	10
Schwarzschild, MA	7
Sultan, ZW	1
Jaeckel, ER	1
Krause, BM	1
Grady, SM	1
Murphy, CA	1
Sanders, RD	1
Banks, MI	1
Abuirmeileh, AN	1
Abuhamdah, SM	1
Ashraf, A	1
Alzoubi, KH	3
Villanueva-García, D	1
Mota-Rojas, D	1
Miranda-Cortés, A	1
Ibarra-Ríos, D	1
Casas-Alvarado, A	1
Mora-Medina, P	1
Martínez-Burnes, J	1
Olmos-Hernández, A	1
Hernández-Avalos, I	1
Evans, MJ	1
Jenkins, MD	1
Berry, JN	1
Arauz, J	1
Zarco, N	1
Hernández-Aquino, E	1
Galicia-Moreno, M	1
Favari, L	1
Segovia, J	1
Muriel, P	1
Fujita, T	1
Feng, C	1
Takano, T	1
Brunquell, J	1
Morris, S	1
Snyder, A	1
Westerheide, SD	1
Dede, F	1
Karadenizli, S	1
Özsoy, ÖD	1
Eraldemir, FC	1
Şahin, D	1
Ateş, N	1
Roldán, M	1
Echeverry-Alzate, V	1
Bühler, KM	1
Sánchez-Diez, IJ	1
Calleja-Conde, J	1
Olmos, P	1
Boehm, SL	3
Maldonado, R	2
Rodríguez de Fonseca, F	1
Santiago, C	1
Gómez-Gallego, F	1
Giné, E	1
López-Moreno, JA	1
Szopa, A	3
Doboszewska, U	1
Herbet, M	1
Wośko, S	3
Wyska, E	2
Świąder, K	1
Serefko, A	3
Korga, A	1
Wlaź, A	3
Wróbel, A	2
Ostrowska, M	1
Terlecka, J	1
Kanadys, A	1
Poleszak, E	3
Dudka, J	1
Wlaź, P	3
Wang, C	1
Zhou, Y	2
Guan, X	1
Yu, M	1
Wang, H	4
Zhong, X	2
Vallmitjana, A	2
Sun, B	1
Xiao, Z	1
Guo, W	1
Wei, J	2
Ni, M	1
Chen, Y	2
O'Brien, ER	1
Gillis, AM	1
Hoshijima, M	1
Takeshima, H	1
Hove-Madsen, L	2
Benitez, R	2
Belke, D	1
Wayne Chen, SR	2
Helal, MG	1
Ayoub, SE	1
Elkashefand, WF	1
Ibrahim, TM	1
Souza, A	1
Martins, DF	3
Medeiros, LF	1
Nucci-Martins, C	1
Martins, TC	1
Siteneski, A	1
Caumo, W	1
Dos Santos, ARS	1
Torres, ILS	1
Schulz, D	1
Chao, OY	1
Yunger, R	1
Yang, YM	1
Ahmad, A	1
Sattar, M	1
Khan, SA	1
Abdullah, NA	1
Johns, EJ	2
Afzal, S	1
Evans, E	1
Piccio, L	1
Cross, AH	1
Assis, MS	1
Soares, AC	1
Sousa, DN	1
Eudes-Filho, J	1
Faro, LRF	1
Carneiro, FP	1
Silva, MV	1
Motoyama, AB	1
Souza, GMR	1
Marchiori, S	1
Lima, NT	1
Boëchat-Barros, R	1
Ferreira, VM	1
Pedraza, LK	1
Sierra, RO	1
Lotz, FN	1
de Oliveira Alvares, L	1
Muhammad, M	1
El-Ta'alu, AB	1
Mohammed, MA	1
Yarube, IU	1
Nuhu, JM	1
Yusuf, I	1
Daneji, UA	1
Johannsen, S	1
Türkmeneli, I	1
Isbary, S	1
Roewer, N	1
Schuster, F	1
Tara, E	1
Vitenzon, A	1
Hess, E	1
Khodakhah, K	1
Nishitsuji, K	1
Watanabe, S	1
Xiao, J	1
Nagatomo, R	1
Ogawa, H	1
Tsunematsu, T	1
Umemoto, H	1
Morimoto, Y	1
Akatsu, H	1
Inoue, K	1
Tsuneyama, K	1
Gan, RY	1
Zhang, D	1
Wang, M	2
Corke, H	1
Wen, Y	2
Shangguan, Y	1
Pan, Z	1
Hu, H	1
Magdalou, J	1
Chen, L	3
Ning, YL	1
Yang, N	1
Chen, X	7
Tian, HK	1
Zhao, ZA	1
Zhang, XZ	1
Liu, D	1
Li, P	2
Zhao, Y	2
Peng, Y	1
Wang, ZG	1
Zhou, YG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Adjuvant Effects of Vitamin A and Vitamin D Supplementation on Treatment of Children With ADHD:A Randomized, Double Blind, Placebo-controlled, Multicentric Trial.[NCT04284059]	Phase 4	504 participants (Anticipated)	Interventional	2021-02-25	Recruiting
Longitudinal Study to Assess the Effects of Whole Coffee Cherry Extract (WCCE)[NCT04986956]		323 participants (Actual)	Interventional	2022-02-01	Active, not recruiting
Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates[NCT00609882]		420 participants (Actual)	Interventional	2007-12-31	Completed
Humidified High Flow Nasal Cannula Versus Nasal Intermittent Positive Ventilation in Neonates as Primary Respiratory Support:a Randomized Controlled Trial[NCT02499744]	Phase 1	200 participants (Anticipated)	Interventional	2016-02-29	Active, not recruiting
The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401]		24 participants (Actual)	Interventional	2016-09-02	Completed
Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea[NCT02494102]	Phase 4	105 participants (Actual)	Interventional	2016-02-29	Terminated
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults[NCT00626210]	Phase 4	2 participants (Actual)	Interventional	2008-02-29	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Length of time of above compared between groups (NCT02494102)
Timeframe: 24 hours

Postanesthesia Quality Recovery Scale Score

Intervention	minutes (Mean)
Placebo	53.5
Modafinil	61.0

Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome. (NCT02494102)
Timeframe: baseline and 6 hours after surgery

Article	Year
Effects of Caffeine Consumption on Attention Deficit Hyperactivity Disorder (ADHD) Treatment: A Systematic Review of Animal Studies. Nutrients, 2022, Feb-10, Volume: 14, Issue:4 Topics: Animals; Attention Deficit Disorder with Hyperactivity; Caffeine; Disease Models, Animal; Dopamine;	2022
Do caffeine and more selective adenosine A Parkinsonism & related disorders, 2020, Volume: 80 Suppl 1 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Humans; Neu	2020
Caffeine: cardiorespiratory effects and tissue protection in animal models. Experimental animals, 2021, Nov-10, Volume: 70, Issue:4 Topics: Animals; Caffeine; Disease Models, Animal; Heart Rate; Mice; Protective Agents; Rats; Respiratory Fu	2021
Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review. JAMA neurology, 2018, 08-01, Volume: 75, Issue:8 Topics: Acetylcarnitine; Animals; Ascorbic Acid; Biotin; Caffeine; Creatine; Curcumin; Dietary Supplements;	2018
Health Benefits of Bioactive Compounds from the Genus Nutrients, 2018, Nov-05, Volume: 10, Issue:11 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Obesity Agents; Antineoplastic Agents	2018
Coffee: biochemistry and potential impact on health. Food & function, 2014, Volume: 5, Issue:8 Topics: Alkaloids; Animals; Antioxidants; Caffeine; Cardiovascular Diseases; Chlorogenic Acid; Coffee; Diabe	2014
Functional foods as potential therapeutic options for metabolic syndrome. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2015, Volume: 16, Issue:11 Topics: Animals; Anthocyanins; Antioxidants; Caffeine; Dietary Fiber; Disease Models, Animal; Ellagic Acid;	2015
Caffeine and cardiovascular diseases: critical review of current research. European journal of nutrition, 2016, Volume: 55, Issue:4 Topics: Animals; Blood Vessels; Caffeine; Cardiovascular Diseases; Clinical Studies as Topic; Coffee; Diseas	2016
Coffee consumption, obesity and type 2 diabetes: a mini-review. European journal of nutrition, 2016, Volume: 55, Issue:4 Topics: Animals; Blood Glucose; Caffeine; Chlorogenic Acid; Coffee; Diabetes Mellitus, Type 2; Disease Model	2016
Health benefits of methylxanthines in neurodegenerative diseases. Molecular nutrition & food research, 2017, Volume: 61, Issue:6 Topics: Animals; Cacao; Caffeine; Coffee; Disease Models, Animal; Humans; Ilex paraguariensis; Meta-Analysis	2017
Adenosine receptors and caffeine in retinopathy of prematurity. Molecular aspects of medicine, 2017, Volume: 55 Topics: Animals; Caffeine; Disease Models, Animal; Humans; Infant, Newborn; Oxygen; Purinergic P1 Receptor A	2017
Molecular Bases Underlying the Hepatoprotective Effects of Coffee. Nutrients, 2017, Jan-23, Volume: 9, Issue:1 Topics: Animals; Caffeine; Chlorogenic Acid; Coffee; Disease Models, Animal; Fatty Liver; Humans; Lipid Meta	2017
The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. Journal of leukocyte biology, 2009, Volume: 86, Issue:3 Topics: Acute Lung Injury; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models,	2009
Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. Journal of Alzheimer's disease : JAD, 2010, Volume: 20 Suppl 1 Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Caffeine; Disease Models, Animal; Humans; Parkinson	2010
Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. Journal of Alzheimer's disease : JAD, 2010, Volume: 20 Suppl 1 Topics: Animals; Caffeine; Disease Models, Animal; Humans; Learning Disabilities; Models, Biological; Motor	2010
Caffeine and coffee as therapeutics against Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2010, Volume: 20 Suppl 1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Caffeine; C	2010
Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. Journal of Alzheimer's disease : JAD, 2010, Volume: 20 Suppl 1 Topics: Animals; Brain; Brain Diseases; Caffeine; Central Nervous System Stimulants; Disease Models, Animal;	2010
Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacological reports : PR, 2011, Volume: 63, Issue:1 Topics: Animals; Anticonvulsants; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Drug	2011
Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins. Current molecular medicine, 2002, Volume: 2, Issue:4 Topics: Animals; Caffeine; Calcium; Disease Models, Animal; Dogs; Female; Genotype; Humans; Hydrogen-Ion Con	2002
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cellular and molecular neurobiology, 2002, Volume: 22, Issue:3 Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian	2002
[Experimental provocation of panic attacks as a human experimental model for anxiety]. Der Nervenarzt, 2003, Volume: 74, Issue:9 Topics: Anxiety Disorders; Atrial Natriuretic Factor; Bicarbonates; Caffeine; Disease Models, Animal; Lactat	2003
Antinociception and the new COX inhibitors: research approaches and clinical perspectives. CNS drug reviews, 2003,Fall, Volume: 9, Issue:3 Topics: Adrenergic Agonists; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Cycloox	2003
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A1 Receptor Antagonists; Adenosine A2 Recept	2003
Lost in translation: taking neuroprotection from animal models to clinical trials. Experimental neurology, 2004, Volume: 188, Issue:2 Topics: Animals; Brain Ischemia; Caffeine; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combin	2004
Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. Journal of the neurological sciences, 2006, Oct-25, Volume: 248, Issue:1-2 Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Central Nervous System; Clinical Trials, Phase	2006
[Effects of coffee and caffeine on fertility, reproduction, lactation, and development. Review of human and animal data]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1994, Volume: 23, Issue:3 Topics: Animals; Caffeine; Child Development; Coffee; Disease Models, Animal; Dose-Response Relationship, Dr	1994
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 1998, Volume: 106 Suppl 2 Topics: Adrenergic beta-Agonists; Animals; Appetite Depressants; Caffeine; Central Nervous System Stimulants	1998
Tea and tea polyphenols in cancer prevention. Advances in experimental medicine and biology, 2001, Volume: 492 Topics: Animals; Biological Availability; Caffeine; Catechin; Disease Models, Animal; Flavonoids; Humans; In	2001
Psychobiology of anxiety and anxiety disorders. The Psychiatric clinics of North America, 1985, Volume: 8, Issue:1 Topics: Animals; Anxiety; Anxiety Disorders; Blood Platelets; Caffeine; Carbolines; Carbon Dioxide; Cats; Di	1985
On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats. Acta neurologica Scandinavica. Supplementum, 1972, Volume: 50 Topics: Amphetamine; Animals; Basal Ganglia; Caffeine; Catalepsy; Cocaine; Compulsive Behavior; Corpus Stria	1972

caffeine and Disease Models, Animal

Research Excerpts

Research

Studies (371)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Length of Time From Extubation to Discharge From Postanesthesia Recovery Unit

Postanesthesia Quality Recovery Scale Score

Nocturnal Sleep Length at 1 Month

Reviews

Trials

Other Studies